VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon
| Autor: | Xian Tuan Tang, Xia Wang, Xiu Cheng Pan, Jian Jun Li, Jun Yan Wang, Ben Shan, Li Li, Juanjuan Fu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty HBsAg Adolescent Genotype medicine.disease_cause Antiviral Agents Gastroenterology Young Adult 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Pegylated interferon Virology Internal medicine medicine Vitamin D and neurology Humans Hepatitis B e Antigens Prospective Studies 030212 general & internal medicine Hepatitis Hepatitis B virus Hepatitis B Surface Antigens Polymorphism Genetic business.industry Interferon-alpha Odds ratio Hepatitis B medicine.disease Treatment Outcome Infectious Diseases HBeAg Receptors Calcitriol Female 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Journal of Medical Virology. 91:765-774 |
| ISSN: | 0146-6615 |
| DOI: | 10.1002/jmv.25373 |
| Popis: | AIM To evaluate the predictive value of vitamin D and its metabolic pathway gene polymorphisms in response to pegylated interferon (Peg-IFN) in hepatitis B early antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. METHODS One hundred and nineteen HBeAg-positive CHB patients who received Peg-IFN monotherapy for 48 weeks and then were followed-up for another 48 weeks were prospectively enrolled; baseline 25-hydroxy vitamin D (25-(OH)D) and hepatitis B virus serologic marker levels were detected, nine critical single nucleotide polymorphisms within vitamin D metabolism were genotyped. RESULTS Forty-five (37.8%), 44 (37.0%), 35 (29.4%), and 11 (9.2%) of the patients achieved virological response (VR), HBeAg loss, combined response (CR), and hepatitis B surface antigen (HBsAg) level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text